Preview Newsletter
XARELTO Media Monitoring – Week of 03-24-16
-
Plaintiffs See Xarelto Lawsuit Numbers Grow To More Than 3,400 Cases Within 5 Years
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the number of Xarelto lawsuits filed over the last 5 years which have now surpassed 3,400 in number. In 2011, the new-generation anticoagulant gained approval from the U.S. Food and Drug Administration (FDA). When the drug initially went to market, it was tremendously popular and brought in lots of money for manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The drug was approved to treat patients recovering from hip and knee replacement surgeries, as well as those suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation condition. -
Xarelto Lawsuit Plaintiff Claims Anticoagulant Caused Bleeding Death Of Grandmother
Mar 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation ) in reference to their new-generation, blood-thinning drug, Xarelto. The complaint was filed in a U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-05874 by a granddaughter on behalf of her grandmother who is now deceased. The plaintiff claims that her grandmother died after experiencing a sudden and severe bleed while taking Xarelto. -
Xarelto Lawsuit Update: 40 Cases To Be Selected For Bellwether Trials
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an update to MDL No. 2592 indicating that 40 cases will be chosen for the Xarelto bellwether pool. According to an order issued by presiding Judge Eldon E. Fallon, both the defense and the plaintiffs will have the opportunity to select 10 cases to be included in the discovery pool and 20 more cases will be selected randomly and proportionally to each state. -
An Overview Of Side Effects Alleged By Xarelto Lawsuit Plaintiffs
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). The plaintiff filing the suit is a south Florida resident, and is filing on behalf of her deceased husband whom she alleges passed away due to bleeding complications which arose from his use of the anticoagulant drug Xarelto. The wife claims the manufacturers Bayer and Janssen neglected their duty to adequately warn consumers of the potentially dangerous bleeding risks she associates with their product. -
Plaintiff Files Xarelto Lawsuit Claiming Blood Thinner Caused Husband’s Death Via Fatal Bleed
|
-
Plaintiffs In Texas File Xarelto Lawsuit Claiming Manufacturers Failed To Properly Warn Consumers Of Drugs Dangerous Side Effects
Mar 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). Xarelto is a new-generation blood thinner. The lawsuit regarding the drug was filed by a couple from Texas. Their complaint was initially filed in the Eastern District of New York under case number 1:14-cv-04524, before being transferred to join other consolidated cases in Louisiana. The plaintiffs involved claim that defendants Bayer and Janssen failed to sufficiently warn consumers and medical professionals about the potentially dangerous risks linked to the use of their product. -
Xarelto Lawsuit Plaintiffs Note Investigation Surrounding Potentially Invalid Trial Results Due To Defective Device
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com announces details from a report published by Reuters detailing an investigation by U.S. and European drug regulators which has been started in order to determine whether a defective blood clotting test device may have impacted trial results conducted on new-generation anticoagulant Xarelto. -
A Lawsuit Comparison Of Pradaxa And Xarelto
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on lawsuits filed against the Pradaxa manufacturers, Boehringer Ingelheim Pharmaceuticals, and Xarelto manufacturers, Johnson & Johnson and Bayer. Both drug manufacturers have faced thousands of lawsuits for the alleged negative side effects of their blood-thinning drugs. While Pradaxa hit the market in the U.S. in October 2010, Xarelto debuted only a year later when it was approved by the FDA in 2011. -
Xarelto Lawsuit Numbers Rise Highlighting New Concern Over Anticoagulants Once-Daily Dosing Recommendation
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer Healthcare in a Pennsylvania State Court. This lawsuit is especially notable as it brings up a new concern that thousands of others have not, indicating that the recommended dosage on the drug (of one pill every 24-hours) is ineffective at protecting patients for a full day. -
Xarelto Lawsuit Plaintiffs Note New York Times Article Detailing Controversies Behind Xarelto Clinical Trials
Mar 22, 2016 | Bloodthinnerhelp.com
By Jospeh Osborne
BloodThinnerHelp.com reports on an article recently published by the New York Times which stated that the U.S. Food and Drug Administration will begin to investigate whether a recalled testing device may have affected the results of clinical trials conducted on new-generation blood-thinning drug Xarelto, ultimately leading to its FDA approval. -
An Overview Of Side Effects Alleged By Xarelto Lawsuit Plaintiffs
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the adverse side effects alleged by plaintiffs in cases against Xarelto manufacturers, Johnson & Johnson and Bayer AG. Plaintiffs in the cases have claimed that the drug caused serious side effects about which they were not adequately warned. -
Xarelto Lawsuit Numbers Increase In Philadelphia Mass Tort
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the increased number of cases added to the Philadelphia mass tort for cases involving the blood thinning drug Xarelto. Plaintiffs have alleged that after using Xarelto, manufactured by Johnson & Johnson and Bayer AG, they have suffered negative side effects that they claim were not properly disclosed to them. -
Deadline Determined For Proposal of Case Management in Xarelto Lawsuit Groups
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the recent deadline decision regarding a Case Management Order for the bellwether trials involving Xarelto. In Case Management Order No. 3, Judge Eldon Fallon, who will be presiding over the bellwether trials, announced that in order to select cases for trials, “The parties are to meet and confer before June 10, 2016 to propose a Case Management Order to address the selection method for bellwether plaintiff cases for trial. The parties will submit the proposed Case Management Order to the Court by July 1, 2016.” -
Xarelto Lawsuit Plaintiff Alleges Anticoagulant Caused Fathers Parenchymal Hemorrhage And Subsequent Death
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG regarding their anticoagulant. The complaint is merely one of thousands which were filed from plaintiffs across the United States. Federally-filed cases were later transferred to a single court in Eastern Louisiana when they were consolidated by the U.S. Judicial Panel on Multidistrict Litigation. These cases now number more than 2,800 and makeup MDL number 2592. The plaintiffs currently involved in the MDL share similar allegations that Xarelto places patients at risk for sudden and dangerous bleeding episodes that can leave lifelong injuries or prove fatal. -
Xarelto Lawsuit Filed For Alleged Omission Of Data
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recent charges filed against Xarelto makers Johnson & Johnson and Bayer AG for allegedly leaving out data that may have been important in determining the blood-thinning drug’s safety. -
Group of Seven Plaintiffs Brings Claims Against Xarelto
Mar 21, 2016 | Bloodthinnerhelp.com
By Roopal Luhana
A group of plaintiffs has filed a new Xarelto lawsuit in the current MDL, proceeding in the U.S. District Court for the Eastern District of Louisiana. The plaintiffs include three families who lost loved ones allegedly because of serious Xarelto side effects, as well as individuals who suffered significant injuries after using the blood-thinning drug. -
Xarelto Lawyers' Caseloads Grow, More than 3,000 Lawsuits Across US
| Drug Justice
By Jordan Hesch
It’s been only five years since Xarelto was approved for medical use by the U.S. Food and Drug Administration, but already the blood thinner is the subject of more than 3,000 lawsuits. While all pharmaceutical companies expect lawsuits concerning the side effects of prescription drugs, this particular drug is bringing up an unusual amount of litigation. Now Xarelto lawyers (meaning, lawyers representing consumers with Xarelto claims) are filling up their caseloads. So much so, in fact, that many of these cases are being consolidated into large class-action suits which will be heard in Eastern District Court of the state of Louisiana.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Plaintiffs See Xarelto Lawsuit Numbers Grow To More Than 3,400 Cases Within 5 Years
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the number of Xarelto lawsuits filed over the last 5 years which have now surpassed 3,400 in number. In 2011, the new-generation anticoagulant gained approval from the U.S. Food and Drug Administration (FDA). When the drug initially went to market, it was tremendously popular and brought in lots of money for manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The drug was approved to treat patients recovering from hip and knee replacement surgeries, as well as those suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation condition.
Today, the initial popularity of Xarelto has worn off some, and many consider the blood thinner to be incredibly dangerous. More than 3,400 lawsuits have been filed against Bayer and Janssen in reference to Xarelto and the dangers that plaintiffs allege it poses. These lawsuits have been filed by plaintiffs from all over the country, who share strikingly similar allegations that the blood thinner can cause increased risk of serious bleeding episodes in patients taking it, some of which plaintiffs claim have proven fatal for their loved ones.
These lawsuits, which continue to increase in number, were consolidated to form two major lawsuit groupings. In Eastern Louisiana, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred all federally-filed Xarelto complaints to a single court. This consolidation formed Multidistrict Litigation No. 2592, which is being overseen by the Honorable Judge Eldon Fallon. The complaints involved in this MDL number over 2,800 at this time, and are joined by another group of more than 600 others which were consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas, forming a mass tort program.
Xarelto has also been given two ‘black box’ warnings from the FDA. These warnings are the most strict warnings a product can receive before being pulled completely from the market. The drug and manufacturers have been in the spotlight again recently as new controversies have been exposed. European Regulators announced that they were starting an investigation regarding the clinical trials conducted on the drug, and on data (or a lack of data) which was provided to prestigious medical journals after clinical trials, which may have led to a premature FDA approval for Xarelto.
As the plaintiffs currently involved await additional answers from these pending investigations, Attorney Joseph Osborne is working to help ensure that everyone who has taken Xarelto and who has suffered from health complications that they attribute to their use of the drug will be given the important opportunity to explore their legal rights in full. These individuals may be entitled to legal action and substantial compensation. To better help patients looking to pursue justice, Attorney Osborne is currently offering free legal consultations for those affected.
To ask questions regarding Xarelto lawsuits, or to request additional information, please contact Attorney Osborne by calling (866) 425-8902.
http://www.wowktv.com/story/31532045/plaintiffs-see-xarelto-lawsuit-numbers-grow-to-more-than-3400-cases-within-5-years
-
Xarelto Lawsuit Plaintiff Claims Anticoagulant Caused Bleeding Death Of Grandmother
Mar 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation ) in reference to their new-generation, blood-thinning drug, Xarelto. The complaint was filed in a U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-05874 by a granddaughter on behalf of her grandmother who is now deceased. The plaintiff claims that her grandmother died after experiencing a sudden and severe bleed while taking Xarelto.
According to further details in lawsuit documents, the grandmother had been prescribed Xarelto to treat her deep vein thrombosis condition in September 2014. Only two months later, the woman suddenly developed a brain bleed. Documents state that doctors called the bleed “irreversible and fatal” after unsuccessfully attempting to clot the blood.
Today, the granddaughter has filed a wrongful death suit alleging that Xarelto caused her grandmother’s brain bleed and subsequent death. She indicates that because her grandmother’s blood was thinned, it would not clot despite physicians attempts. She indicates that had she been better made aware of these dangers, she would have helped her grandmother to select an alternative treatment.
This case will now join with more than 2,800 others which have been filed against Xarelto by plaintiffs from across the U.S. who allege strikingly similar complaints. Lawsuits which were federally-filed have been transferred to a single court by the U.S. Judicial Panel on Multidistrict Litigation and formed into MDL 2592. These lawsuits are also joined by more than 600 cases in Philadelphia, Pennsylvania which were formed into a mass tort program by the Court of Common Pleas. Together, these Xarelto lawsuits number over 3,400, and continue to grow in number today.
As the many plaintiffs involved await trial, Attorney Joseph Osborne is working to assist anyone who used Xarelto and suffered from health problems that they attribute to the drug. These patients deserve the important opportunity to evaluate their legal rights in the matter. Patients who have suffered may be entitled to significant compensation through legal action. To assist those wishing to pursue justice, Attorney Osborne is currently offering free legal consultations for affected parties.
To request further information on Xarelto lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.keyc.com/story/31532289/xarelto-lawsuit-plaintiff-claims-anticoagulant-caused-bleeding-death-of-grandmother
-
Xarelto Lawsuit Update: 40 Cases To Be Selected For Bellwether Trials
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on an update to MDL No. 2592 indicating that 40 cases will be chosen for the Xarelto bellwether pool. According to an order issued by presiding Judge Eldon E. Fallon, both the defense and the plaintiffs will have the opportunity to select 10 cases to be included in the discovery pool and 20 more cases will be selected randomly and proportionally to each state.
The order indicates that five plaintiffs will be selected by plaintiffs and five plaintiffs will be selected by the defense in the Eastern District of Louisiana with ten plaintiffs selected randomly. Mississippi plaintiffs will be determined after one plaintiff is selected by the defense and one is selected by plaintiffs, with two selected randomly. For Texas, one plaintiff will be selected by plaintiffs and one will be selected by the defense. Plaintiffs will then be able to choose 7 states in which five plaintiffs will be selected by the plaintiffs and 2 plaintiffs will be selected randomly. The same opportunity will be given to the defense, according to the order.
A multidistrict litigation panel was created in 2014 in Eastern Louisiana for the efficient management of cases. Since its creation, MDL No. 2592 has reached almost 3,000 cases in which plaintiffs allege that using the blood-thinning drug Xarelto caused them negative side effects. Many individuals filing cases claim that manufacturers, Bayer AG and Johnson & Johnson, did not adequately warn them about the possibility of adverse side effects such as gastrointestinal bleeding, brain hemorrhages, internal bleeding, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks. The first bellwether trials are expected to begin in February 2017.
As bellwether trial dates approach, Attorney Joseph Osborne is working to ensure that those who believe they have been negatively affected by the drug are able to explore their legal rights. Those individuals may be entitled to legal action and substantial financial compensation. Osborne is currently offering free legal consultations to qualifying parties.
For more information, or to ask questions about Xarelto, contact Joseph Osborne, Esq. by call (866) 425-8902.
http://www.fox5vegas.com/story/31534279/xarelto-lawsuit-update-40-cases-to-be-selected-for-bellwether-trials#ixzz43e3DjnSq
-
An Overview Of Side Effects Alleged By Xarelto Lawsuit Plaintiffs
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). The plaintiff filing the suit is a south Florida resident, and is filing on behalf of her deceased husband whom she alleges passed away due to bleeding complications which arose from his use of the anticoagulant drug Xarelto. The wife claims the manufacturers Bayer and Janssen neglected their duty to adequately warn consumers of the potentially dangerous bleeding risks she associates with their product.
The widow’s lawsuit has been filed under case number 9:14-cv-80831 in Florida but, during the U.S. JPML’s consolidation of all federally-filed Xarelto lawsuits, it was transferred to the Eastern District of Louisiana. Today, it joins with more than 2,800 other similar lawsuits to become a part of MDL No. 2592. The MDL is being overseen by the Honorable Judge Eldon Fallon.
Details of this particular lawsuit show that the plaintiff claims the defendants are to blame for the death of her husband. Within her court documents, the widow indicates that his death was caused by a sudden and fatal episode of uncontrollable internal bleeding. He suffered from this hemorrhaging while using Xarelto, which made it impossible for doctors to clot his blood. The man ultimately passed away from a subdural hemorrhage. According to the plaintiff, her husband was taking Xarelto to treat his atrial fibrillation condition.
Xarelto has now become the topic of over 2,800 federally-filed lawsuits from across the United States, in addition, there are more than 600 cases which were formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Xarelto has also been the recipient of two “black-box” warnings from the FDA. These warnings are the most strict warnings possible to be given before a product is fully removed from the market.
As many plaintiffs like this widow await their day in court, Attorney Joseph Osborne is working to assist anyone who used Xarelto and who believes they have been negatively affected by the drug. He wants to ensure that these people will be given the important opportunity to investigate their legal rights in full. Affected patients could be entitled to significant compensation through legal action. To better assist those seeking justice, Attorney Osborne is currently offering free legal consultations for qualified parties.
To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2874346
-
Plaintiff Files Xarelto Lawsuit Claiming Blood Thinner Caused Husband’s Death Via Fatal Bleed
|
-
Mar 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). Xarelto is a new-generation blood thinner. The lawsuit regarding the drug was filed by a couple from Texas. Their complaint was initially filed in the Eastern District of New York under case number 1:14-cv-04524, before being transferred to join other consolidated cases in Louisiana. The plaintiffs involved claim that defendants Bayer and Janssen failed to sufficiently warn consumers and medical professionals about the potentially dangerous risks linked to the use of their product.
Details found within court documents of this particular complaint indicate that the female plaintiff was prescribed Xarelto by her doctor in an attempt to prevent strokes from occurring due to her atrial fibrillation condition. The woman claims that she had taken the anticoagulant for just 5 months when she suddenly suffered from a potentially life-threatening internal bleed. She states that the bleed has left her with long-term medical needs that she continues to deal with today.
Xarelto launched onto the market in 2011 after gaining U.S. Food and Drug Administration (FDA) approval. It was approved to treat patients recovering from knee and hip surgeries, as they may be at increased risk for the development of blood clots or strokes, as well as patients with pulmonary embolism, deep vein thrombosis, or atrial fibrillation.
Although Xarelto was initially incredibly popular among consumers, today the drug is surrounded by over 3,000 lawsuits involving plaintiffs who all share strikingly similar allegations. These plaintiffs state the blood thinner can put users at increased risk for sudden and dangerous bleeding episodes. Federally-filed complaints which were consolidated in Louisiana by the U.S. JPML now number over 2,800 while another group forming a mass tort is housed in Philadelphia, Pennsylvania containing more than 600 Xarelto lawsuit cases. Cases in Louisiana have formed MDL No. 2592 and are being overseen by Judge Eldon Fallon.
As thousands of plaintiffs await their trial dates, and lawsuits continue to increase in number, Attorney Joseph Osborne has been working to help anyone who used Xarelto and feels that they have been negatively affected by the blood thinner. He wants to provide these patients with the important opportunity to explore their legal rights in full. Those who suffered after using the drug may be entitled to significant compensation through legal action. To help those wishing to pursue justice, Attorney Osborne is currently offering free legal consultations to affected individuals.
To request more information or ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.cbs19.tv/story/31515729/plaintiffs-in-texas-file-xarelto-lawsuit-claiming-manufacturers-failed-to-properly-warn-consumers-of-drugs-dangerous-side-effects
-
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com announces details from a report published by Reuters detailing an investigation by U.S. and European drug regulators which has been started in order to determine whether a defective blood clotting test device may have impacted trial results conducted on new-generation anticoagulant Xarelto.
Xarelto is the topic of much recent controversy as the drug is currently the subject of over 3,400 lawsuits. These lawsuits were filed by plaintiffs from across the country who share common allegations that the drug can cause heightened risk of sudden and dangerous bleeding episodes among patients, some of which have been fatal. The lawsuits have formed two main groups: MDL number 2592 in Eastern Louisiana, where more than 2,800 cases have been transferred, and more than 600 cases which have been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
The trial now being investigated was conducted in order to compare the clotting effects of Xarelto to those of traditional blood thinner warfarin. Researchers conducting the studies were asked to evaluate the overall effectiveness of each drug in preventing strokes among patients with atrial fibrillation. Since the trial was completed, however, it has been discovered that one of the pieces of medical equipment used was recalled and was potentially faulty.
European Medicines Agency officials discussed this possibility, noting, “Due to the defect, it is now thought that the INR (international normalized ration) device may have impacted the clotting results in some patients in the warfarin group,” They also announced that they would not publish any of the trial’s results until the investigation concerning the accuracy of those results had finished. The medical device in question is called an INR. It works to measure how quickly blood is able to clot. It has been indicated that the device used during this study was recalled in December of 2014.
Plaintiffs currently involved in the Xarelto cases are awaiting trial, and lawsuit numbers continue to grow as time moves on. Attorney Joseph Osborne is working to ensure that anyone who feels they were negatively affected by Xarelto will be given the important opportunity to fully explore their legal rights in the matter. Patients who took Xarelto and also suffered from health problems could be entitled to significant compensation gained through legal action. To help assist those wishing to pursue justice, Attorney Osborne is now offering free Xarelto consultations to affected parties.
To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.fox5vegas.com/story/31532288/xarelto-lawsuit-plaintiffs-note-investigation-surrounding-potentially-invalid-trial-results-due-to-defective-device#ixzz43eGVaNdH
-
A Lawsuit Comparison Of Pradaxa And Xarelto
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on lawsuits filed against the Pradaxa manufacturers, Boehringer Ingelheim Pharmaceuticals, and Xarelto manufacturers, Johnson & Johnson and Bayer. Both drug manufacturers have faced thousands of lawsuits for the alleged negative side effects of their blood-thinning drugs. While Pradaxa hit the market in the U.S. in October 2010, Xarelto debuted only a year later when it was approved by the FDA in 2011.
Following its debut, thousands reported suffering serious side effects. Those side effects mentioned by Pradaxa users included many of the same ones alleged by users of Xarelto including gastrointestinal bleeding, internal bleeding, stroke and heart attack. Just as a multidistrict litigation panel was formed in Illinois for plaintiffs involved in the cases against Pradaxa, another panel was formed in Eastern Louisiana in 2014 for those patients who claim Xarelto has caused them pain and suffering. MDL No. 2592 in Louisiana has now reached close to 3,000 cases and a bellwether trial is set for January 2017.
Boehringer Ingelheim, however, eventually stated that it would pay $650 million for both state and federal Pradaxa lawsuits to be settled. Plaintiffs alleging Xarelto has caused them health problems have not yet been so lucky.
Most lawsuits allege that Xarelto caused uncontrollable internal bleeding resulting in death or serious injury. Despite thousands of lawsuits, Xarelto is anticipated to be the 19th best selling drug in the world and will generate 3.7 billion US Dollars in sales by 2018, which is up from the $596 million it generated in 2012, according to EvaluatePharma in its World Preview.
As many Xarelto plaintiffs await court dates, Attorney Joseph Osborne is working to make sure that those who claim they have been negatively affected by the blood-thinning drug are given the opportunity to explore their legal rights. Osborne is currently offering free consultations to qualifying parties and those affected may be entitled to financial compensation.
For more information, or to ask questions about Xarelto, contact Attorney Joseph Osborne at (866) 425-8902.
Read more: http://www.fox5vegas.com/story/31542658/a-lawsuit-comparison-of-pradaxa-and-xarelto#ixzz43kXho2wqhttp://www.fox5vegas.com/story/31542658/a-lawsuit-comparison-of-pradaxa-and-xarelto
-
Mar 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer Healthcare in a Pennsylvania State Court. This lawsuit is especially notable as it brings up a new concern that thousands of others have not, indicating that the recommended dosage on the drug (of one pill every 24-hours) is ineffective at protecting patients for a full day.
Xarelto is the only anticoagulant to ever offer a one pill daily dose. Other blood-thinning drugs require 2 pills of medication to be taken each day in order to ensure that the body is properly protected for a full 24-hours. The specific complaints found within this suit state that the drug’s recommended once-daily dose is ineffective for an entire 24-hour period of time. The plaintiff in this notable lawsuit claims just this. He claims to have suffered from a sudden stroke just four days after starting Xarelto. He was prescribed the drug in order to prevent strokes which he was at elevated risk for experiencing due to his atrial fibrillation condition.
Following his stroke, the plaintiff indicates that he decided to file a lawsuit on October 8th of 2015. He named Xarelto manufacturers Bayer and Janssen as his defendants. The lawsuit is the first of its kind to have been filed, though thousands of others have been filed concerning Xarelto and sudden, dangerous bleeding episodes. Not only did the plaintiff allege that Xarelto failed to prevent his stroke, he also claims that the drug may have actually caused the stroke to occur.
Within the last five years, Xarelto has become the topic of over 2,800 lawsuits filed in federal court and over 600 complaints which have been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. The anticoagulant drug was approved by the U.S. Food and Drug Administration in 2011 to prevent strokes and blood clots for those recovering from knee and hip replacement surgeries, as well as deep vein thrombosis, pulmonary embolism, or atrial fibrillation.
Those who have now filed federal Xarelto lawsuits have had their cases transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in a single court in Eastern Louisiana. Lawsuits involved in MDL 2592 are being overseen by the Honorable Judge Eldon E. Fallon.
While the plaintiffs involved in these cases anxiously await justice, lawsuit numbers continue to grow. Attorney Joseph Osborne is working to help ensure that anyone suffering from medical problems after taking Xarelto will be provided the important opportunity to explore their legal rights in full. To help those wishing to pursue justice, Attorney Osborne is currently offering free consultations to affected parties, who could be entitled to significant compensation through legal action.
To ask questions, or request additional Xarelto lawsuit information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.kcentv.com/story/31542797/xarelto-lawsuit-numbers-rise-highlighting-new-concern-over-anticoagulants-once-daily-dosing-recommendation
-
Mar 22, 2016 | Bloodthinnerhelp.com
By Jospeh Osborne
BloodThinnerHelp.com reports on an article recently published by the New York Times which stated that the U.S. Food and Drug Administration will begin to investigate whether a recalled testing device may have affected the results of clinical trials conducted on new-generation blood-thinning drug Xarelto, ultimately leading to its FDA approval.
Since its 2011 release to market in just five year’s time, Xarelto has become the topic of over 3,400 lawsuits– 2,800 of which were federally-filed, transferred, and consolidated in Eastern Louisiana by the U.S. JPML, and over 600 of which were consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
Thousands of Xarelto plaintiffs filing lawsuits from across the nation share remarkably similar complaints which allege that the anticoagulant causes elevated risk of the development of sudden, dangerous, and even fatal bleeding episodes among patients taking it. The lawsuits concerning these allegations were filed against Xarelto manufacturers Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals.
According to the New York Times article, the FDA has started to ask Johnson & Johnson, “…detailed questions about whether there was evidence that the device was malfunctioning while the trial was underway, according to a legal brief filed in federal court on Monday by lawyers for patients and their families who say they were injured by the drug. The lawyers also cited internal company documents that they said showed doctors were complaining to the trial leadership during the course of the study.”
Much controversy has been stirred up over the accuracy of the clinical trial study and over what information was provided from that study to a prestigious medical journal. It has been reported that questions surrounding the trial results have been growing since last fall when it was reported that Johnson & Johnson and Bayer, “…notified regulators that the device that was used in the trial had been recalled in 2014 because it was understating patients’ risk of bleeding.”
The New York Times additionally mentioned that, “Regulators are looking at whether the malfunctioning device might have led doctors to give patients the wrong dose of warfarin, which could have led to additional bleeding episodes and given an unfair advantage to Xarelto.”
Attorney Joseph Osborne is working to help anyone who has taken Xarelto and who has also suffered from health complications that they feel were caused by the drug. He feels that it is important to help ensure that all affected individuals will be provided an opportunity to explore their legal rights in full. Affected patients could be entitled to substantial compensation through legal action. In an effort to better assist those who wish to pursue justice, Attorney Osborne is currently offering complimentary Xarelto consultations for affected individuals.
To obtain additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902
http://www.keyc.com/story/31542823/xarelto-lawsuit-plaintiffs-note-new-york-times-article-detailing-controversies-behind-xarelto-clinical-trials
-
An Overview Of Side Effects Alleged By Xarelto Lawsuit Plaintiffs
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the adverse side effects alleged by plaintiffs in cases against Xarelto manufacturers, Johnson & Johnson and Bayer AG. Plaintiffs in the cases have claimed that the drug caused serious side effects about which they were not adequately warned.
The drug hit the U.S. market in 2011 when it was approved by the FDA for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, suffering from atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. Most lawsuits allege that the drug caused uncontrollable internal bleeding resulting in death or serious injury but other allegations regarding the side effects of the blood thinner have been brought to court as well. Injuries alleged by plaintiffs include stroke, heart attack, rectal bleeding, gastrointestinal bleeding, epidural hematoma, pulmonary embolism and brain hemorrhages.
Due to the increasing number of cases alleging such side effects, Xarelto cases have been consolidated for more effective processing. A multidistrict litigation panel (MDL No. 2592) was created in New Orleans, Louisiana for cases filed federally. Almost 3,000 cases have now been filed. A mass tort program was also created in Pennsylvania for those cases filed within the commonwealth. That number has now reached 620 cases. Bellwether trials for cases consolidated in the MDL will be presided over by Judge Eldon E. Fallon.They are expected to begin in February 2017 after a total of 40 cases have been selected randomly and by the plaintiffs and the defense.
As those cases alleging adverse side effects approach bellwether trials, Attorney Joseph Osborne is working to ensure that those who have taken the drug and believe they have suffered serious side effects have the opportunity to explore their legal rights fully. Qualifying individuals may be entitled to substantial financial compensation and legal action. Osborne is currently offering complimentary legal consultations for affected individuals.
For more information on Xarelto, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.cbs19.tv/story/31536866/an-overview-of-side-effects-alleged-by-xarelto-lawsuit-plaintiffs
-
Xarelto Lawsuit Numbers Increase In Philadelphia Mass Tort
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the increased number of cases added to the Philadelphia mass tort for cases involving the blood thinning drug Xarelto. Plaintiffs have alleged that after using Xarelto, manufactured by Johnson & Johnson and Bayer AG, they have suffered negative side effects that they claim were not properly disclosed to them.
A Philadelphia mass tort program was established for those cases filed in Pennsylvania state court as a more efficient way to manage litigation. Those numbers have now reached 680 cases. In addition to the mass tort program the JPML has consolidated all federally-filed into MDL No. 2592 in Eastern Louisiana. Cases in the MDL have reached 2,800.
The drug was first introduced in the United States in 2011 and was approved by the FDA for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. When released to the market no known reversal agent for the drug existed and many patients who have used Xarelto reported side effects such as internal bleeding or anemia. Other reported injuries included gastrointestinal bleeding, brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks.
Xarelto has not yet been recalled but the FDA has issued several important safety communications regarding Xarelto as well as two “black box warnings.” Also known as a “boxed warning,” a “black box warning” is the strictest warning that can be issued by the FDA for a drug. It usually refers to the fact that there is “reasonable evidence” that some danger exists in regard to the drug.
The Honorable Judge Eldon E. Fallon is overseeing the litigation and has scheduled the first “bellwether” trial for January 2017. Until then, Attorney Joseph Osborne is working with those affected negatively by the drug. Those individuals will have the opportunity to explore their legal options and may be entitled to significant compensation. Osborne is now offering free legal consultation for those affected.
To request additional information or ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.tucsonnewsnow.com/story/31546883/xarelto-lawsuit-numbers-increase-in-philadelphia-mass-tort
-
Deadline Determined For Proposal of Case Management in Xarelto Lawsuit Groups
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the recent deadline decision regarding a Case Management Order for the bellwether trials involving Xarelto. In Case Management Order No. 3, Judge Eldon Fallon, who will be presiding over the bellwether trials, announced that in order to select cases for trials, “The parties are to meet and confer before June 10, 2016 to propose a Case Management Order to address the selection method for bellwether plaintiff cases for trial. The parties will submit the proposed Case Management Order to the Court by July 1, 2016.”
Plaintiffs first began filing cases against the manufacturers, Johnson & Johnson and Bayer AG, after alleging that the drug caused life-threatening side effects about which the companies did not adequately warn them. The drug was issued two “black box warnings” by the FDA to inform consumers that patients who prematurely discontinued Xarelto were at a higher risk of blood clots, deep vein thrombosis, and epidural/spinal hematoma. Another warning told patients that “placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.”
Side effects reported by patients who used Xarelto include stroke, heart attack, pulmonary embolism, internal bleeding, gastrointestinal bleeding, rectal bleeding, epidural hematoma and brain hemorrhages. Federally, the multidistrict litigation panel in Eastern Louisiana that was created to better manage the large volume of cases has accumulated close to 3,000 lawsuits all alleging similar issues with the drug.
As more cases are expected to be brought to court, Attorney Joseph Osborne is working to ensure that those who have taken Xarelto and believe they have suffered negative side effects as a result of the drug have the opportunity to explore their legal rights. Qualifying individuals may be entitled to legal action and financial compensation. Osborne is currently offering complimentary legal consultations to affected parties.
For more information, or to ask questions about Xarelto, contact Joseph Osborne, Esq. by calling (866) 425-8902.
-
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG regarding their anticoagulant. The complaint is merely one of thousands which were filed from plaintiffs across the United States. Federally-filed cases were later transferred to a single court in Eastern Louisiana when they were consolidated by the U.S. Judicial Panel on Multidistrict Litigation. These cases now number more than 2,800 and makeup MDL number 2592. The plaintiffs currently involved in the MDL share similar allegations that Xarelto places patients at risk for sudden and dangerous bleeding episodes that can leave lifelong injuries or prove fatal.
Details from court documents for this particular lawsuit show that the plaintiff is filing suit on behalf of her deceased father. The case had been filed under number 2:14-cv-00159-cr in a Vermont federal court, but was later transferred to join the MDL. Within court documents, the woman states that her father died after experiencing a sudden and severe brain bleed known as a parenchymal hemorrhage. Her family claims that this bleed was caused by his use of Xarelto, which was in his system at the time of his death. As an anticoagulant, Xarelto had thinned the man’s blood, making it nearly impossible for doctors to clot, and ultimately causing the bleed to be a fatal one.
Xarelto is the subject of two “black box” warnings from the FDA, which are the most strict warnings a product can receive before being pulled from the market completely. The drug is currently the subject of more than 3,400 lawsuits; over 2,800 of which make up the Louisiana MDL and over 600 of which have been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
As the many plaintiffs involved await their day in trial, Attorney Joseph Osborne is working to help any patients who have suffered from health problems after taking Xarelto. He wishes to ensure that these patients will be given the important opportunity to explore their legal rights in full. Those affected may be entitled to significant compensation through legal action. To better help those wishing to pursue justice in the matter, Attorney Osborne is currently offering free legal consultations for involved parties.
To request additional information or ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.wrcbtv.com/story/31552911/xarelto-lawsuit-plaintiff-alleges-anticoagulant-caused-fathers-parenchymal-hemorrhage-and-subsequent-death
-
Xarelto Lawsuit Filed For Alleged Omission Of Data
Mar 23, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recent charges filed against Xarelto makers Johnson & Johnson and Bayer AG for allegedly leaving out data that may have been important in determining the blood-thinning drug’s safety.
Data about Xarelto was published in the New England Journal of Medicine by Duke researchers and is now the main focus of a lawsuit because of an allegedly faulty blood-testing device that was used in the drug trial. The clinical trial, called “Rocket AF” included 14,000 patients over a 3-year period and was compared to the blood-thinning drug warfarin. Companies informed regulators that the blood-testing device had not been working properly during the research trial about five years after the drug had reached the market. As a result, researchers may have given patients the wrong dosage of warfarin, leading to the belief that Xarelto was more effective, the FDA said. Recently lawyers have argued that the companies knowingly ignored Duke’s omission of data regarding a blood-testing device. As a result, they allege that these companies contributed to misleading the NEJM. Both companies assert that they sent all the required data to regulators in Europe and the U.S.
Xarelto was first introduced to the United States in 2011. According to several studies, and adverse events reported by the FDA, Xarelto has been suggested as the primary cause for internal bleeding and gastrointestinal bleeds. The first lawsuit filed alleging Xarelto was the cause of a patient’s death because of uncontrollable bleeding occurred in January 2014. Other common adverse side effects that patients have associated with the drug include brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks. At the time of the drug’s release to the market there was no known reversal agent for Xarelto.
Many believe that Xarelto lawsuits will continue to be filed as trial dates approach. Attorney Joseph Osborne is currently working to assist patients who used Xarelto and believe they have suffered adverse side effects from the drug. Those individuals may be entitled to legal action and compensation. Osborne greatly encourages those affected to investigate their legal opportunities fully. Osborne is offering complimentary legal consultations at this time.
For more information or questions on Xarelto, please contact Joseph Osborne, Esq., by calling (866) 425-8902.
http://www.wrcbtv.com/story/31552946/xarelto-lawsuit-filed-for-alleged-omission-of-data
-
Group of Seven Plaintiffs Brings Claims Against Xarelto
Mar 21, 2016 | Bloodthinnerhelp.com
By Roopal Luhana
A group of plaintiffs has filed a new Xarelto lawsuit in the current MDL, proceeding in the U.S. District Court for the Eastern District of Louisiana. The plaintiffs include three families who lost loved ones allegedly because of serious Xarelto side effects, as well as individuals who suffered significant injuries after using the blood-thinning drug.
The plaintiffs name as defendants manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson, and Bayer Pharma AG. The case was filed on February 8, 2016, with plaintiffs seeking in excess of $75,000 in damages.
Plaintiffs Point to Flaws in Xarelto Clinical Trials
The plaintiffs include the following:
A Kentucky man who claims that after taking Xarelto, he suffered a gastrointestinal bleed.
The daughter of a deceased Alabama woman who took Xarelto for a couple months in 2014 and suffered internal bleeding that led to her death.
The estate representatives of a Colorado man who took Xarelto for about a year and suffered internal bleeding that led to his death.
The daughter of a deceased Georgia woman who took Xarelto for only about a month in 2014 before suffering gastrointestinal bleeding and severe internal bleeding that led to her death.
A Pennsylvania woman who took Xarelto for only about a month before suffering gastrointestinal bleeding on three different occasions.
A Florida individual who took Xarelto for about four months and then suffered internal bleeding.
A Georgia man who took Xarelto and then suffered gastrointestinal bleeding and internal bleeding on two separate occasions.
The plaintiffs noted in their complaint that the “RECORD” studies used to gain FDA approval for Xarelto for the prevention of blood clots in patients going through hip and knee surgery were “flawed in design and conducted in a negligent manner.” They also alleged that after an FDA inspection, four of the studies were found to be so flawed that they were deemed unreliable. Still, the drug was approved for this use.
According to the plaintiffs, the “ROCKET” studies used to gain FDA approval for Xarelto for the prevention of stroke in patients with non-valvular atrial fibrillation were also found to be flawed, in that the warfarin comparative group was not “well managed,” making it easier for Xarelto to appear equal in efficacy to the long-standing anticoagulant.
In support of their position, the plaintiffs quoted from an FDA Advisory Committee Briefing that “the data comparing [Xarelto] to warfarin are not adequate to determine whether [Xarelto] is as effective for its proposed indication in comparison to warfarin with the latter is used skillfully.”
Plaintiffs Question Once-A-Day Dosing
The plaintiffs also point to problems with Xarelto’s once-a-day dosing. The manufacturers used this as a way to establish Xarelto’s superiority to warfarin, calling it more convenient than the twice-a-day dosing required with Warfarin. FDA clinical reviewers, however, stated that the “rationale” for the once-a-day dosing was “not strong,” because clinical studies suggested that twice-a-day dosing would be wiser, as it created more consistent levels of the drug in the bloodstream, reducing the risk of the blood becoming too thin because of high levels, or prone to clotting because of low levels.
According to an FDA advisory meeting transcript, and concern was raised that “the dose was selected more for a marketing advantage rather than for the scientific data that was available, and was a mistake….”
Finally, the plaintiffs point to the fact that there is no reversible agent for Xarelto, so patients who suffer from excessive bleeding must simply wait for the drug to clear from their systems, which can make bleeding side effects particularly dangerous.
According to the plaintiffs, the defendants failed to warn about these risks, misled patients and doctors in their advertisements, and failed to adequately study the drug to eliminate clear safety risks. They bring counts of strict liability, manufacturing and design defects, failure to warn, negligence, breach of warranties, negligent misrepresentation, fraud, loss of consortium, and wrongful death. They seek compensatory and punitive damages.
http://newyork.legalexaminer.com/defective-dangerous-products/group-of-seven-plaintiffs-brings-claims-against-xarelto/
-
Xarelto Lawyers' Caseloads Grow, More than 3,000 Lawsuits Across US
| Drug Justice
By Jordan Hesch
It’s been only five years since Xarelto was approved for medical use by the U.S. Food and Drug Administration, but already the blood thinner is the subject of more than 3,000 lawsuits. While all pharmaceutical companies expect lawsuits concerning the side effects of prescription drugs, this particular drug is bringing up an unusual amount of litigation. Now Xarelto lawyers (meaning, lawyers representing consumers with Xarelto claims) are filling up their caseloads. So much so, in fact, that many of these cases are being consolidated into large class-action suits which will be heard in Eastern District Court of the state of Louisiana.
Why Xarelto Appeared in the First Place
Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, brought Xarelto to market in 2011 as a replacement for the decades-old warfarin. In patients at risk for stroke, a blood-thinning agent is required to break up or prevent life-threatening clots from forming in the blood stream and then traveling to the lungs or heart. Warfarin, while effective, was difficult on patients because it required changes in diet, and constant medical monitoring. Xarelto was marketed as the safe and easy replacement for warfarin. No dietary restrictions, no routine doctor’s visits. Just take your pill and live your life like normal. But by 2012, only a year after its approval for patient use, at least 65 deaths had been reported to the FDA, all associated with Xarelto.
A Runaway Drug
According to subsequent studies and legal claims, Xarelto can become a runaway blood thinner, causing uncontrolled bleeding so severe that not even physicians can stop the fatal side effect. As a result of these findings, an antidote was developed— andexanet alfa— but the drug is only coming available this year.
Even more troubling is the disclosure of information indicating Janssen Pharmaceuticals created deliberately misleading marketing in its effort to corner the blood thinner market. One independent organization, the Institute for Safe Medication Practices, suggested in an official report, that “marketing the drug for ease of use, rather than providing tools to reduce bleeding risk, constitutes a wrong turn for an important medical treatment.”
This isn’t the first time the New Jersey-based drug maker has come under scrutiny for failing to disclose potential health problems to patients. A recent case in Philadelphia awarded $1.75 million in damages to a plaintiff suffering from complications related to Risperdal, an anti-psychotic medication.
Trials Are Taking Place
On Feb 17th of this year, the Louisiana court that is hearing the multidistrict suits against Janssen set deposition dates, and trials are scheduled to take place between February and May of 2017. Patients who have experienced dangerous bleeding as a result of taking Xarelto are invited to join the litigation, which will, if successful, help to pay for medical care associated with the side effects of the drug. In September of 2015, the FDA issued a safety label change, requiring Janssen Pharmaceuticals to clearly represent the potential dangerous side effects of Xarelto in its packaging, physician information, and marketing.
https://www.drugjustice.com/xarelto-lawyers-3000-lawsuits-us/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested